People with intellectual and developmental disabilities (IDD) face some of the most severe oral health disparities in the healthcare system, leading to higher rates of cavities, gum disease, and tooth loss.
Limited access to care, provider training gaps, and sensory or mobility challenges make routine dental visits difficult. Poor oral health also contributes to chronic conditions like heart disease, increasing long-term healthcare costs.
As insurers seek smarter ways to improve outcomes and manage spending, salivary diagnostics are emerging as a promising tool. Non-invasive and real-time, these tests offer preventive solutions for high-risk populations while giving payers a low-risk opportunity to assess impact.
Traditional dental care often falls short for individuals with IDD. Routine cleanings can trigger anxiety, sensory sensitivities, or mobility barriers. Many dentists lack training to treat this population, and specialty clinics are often inaccessible.
Consequently, preventable dental issues escalate into medical problems, driving unnecessary ER visits, worsening chronic conditions, and increasing costs—particularly for Medicaid plans.
Chairside salivary testing addresses these challenges. Quick, non-invasive, and adaptable to various settings such as group homes, clinics, and primary care offices, the tests analyze saliva for biomarkers like pH and MMP-8, detecting early signs of dental disease and systemic inflammation.
This provides caregivers and providers with actionable, real-time insights, enabling interventions before emergencies arise.
The approach is gaining national recognition. The American Dental Association recently approved a CDT code for point-of-care saliva diagnostics, paving the way for broader adoption and reinforcing its role in preventive care.
Early pilot studies indicate improvements in key biomarkers linked to cavity risk and gum health, as well as better preventive habits among participants.
While more research is needed, these initial results suggest salivary diagnostics could support earlier intervention and improved care for high-need populations.
For insurers, the appeal is both clinical and financial. Emergency dental visits cost the U.S. healthcare system over $2 billion annually, with Medicaid covering more than 40%. Preventive tools that flag risk early could reduce avoidable interventions and bend the cost curve.
Chairside salivary testing also requires minimal equipment and can be administered by support staff in non-traditional care settings, making it scalable for underserved IDD populations.
Pilot programs provide an ideal starting point. Payers can target high-risk populations, measure clinical and financial outcomes, and gather real-world data without major policy changes. Partnering with experienced supplemental benefits providers can streamline implementation, data collection, and analysis.
To launch a successful pilot, insurers should:
Define scope: Focus on high-risk IDD members to maximize impact and data clarity.
Leverage expertise: Work with supplemental benefits administrators to ensure smooth execution.
Measure outcomes: Track biomarkers, preventive behaviors, and reductions in emergency visits.
Scale strategically: Use pilot data to expand salivary testing as part of broader preventive care offerings.
The oral health needs of people with IDD have long been neglected, with significant downstream costs. Salivary testing offers a scalable, preventive strategy to reduce emergencies and improve equity in care. With early successes already documented, the question for payers is no longer whether this technology works—but whether they are ready to adopt it.